These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8029479)
1. Inhibition of the pharmacological effects of endothelin. Wilson C; Hargreaves RB Prog Med Chem; 1994; 31():371-410. PubMed ID: 8029479 [No Abstract] [Full Text] [Related]
2. Endothelins are potent vasoconstrictors, and much more besides. Gray GA; Battistini B; Webb DJ Trends Pharmacol Sci; 2000 Feb; 21(2):38-40. PubMed ID: 10733432 [No Abstract] [Full Text] [Related]
5. Endothelin receptor antagonists: actions and rationale for their development. Warner TD; Battistini B; Doherty AM; Corder R Biochem Pharmacol; 1994 Aug; 48(4):625-35. PubMed ID: 8080434 [No Abstract] [Full Text] [Related]
6. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Lüscher TF; Barton M Circulation; 2000 Nov; 102(19):2434-40. PubMed ID: 11067800 [TBL] [Abstract][Full Text] [Related]
7. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Rabelink TJ; Stroes ES; Bouter KP; Morrison P Cardiovasc Res; 1998 Sep; 39(3):543-9. PubMed ID: 9861295 [No Abstract] [Full Text] [Related]
8. Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction of rabbit basilar artery. Zimmermann M; Jung C; Raabe A; Spanehl O; Seifert V Acta Neurochir Suppl; 2001; 77():73-5. PubMed ID: 11563313 [No Abstract] [Full Text] [Related]
9. [Involvement of endothelin in the pathogenesis of hypertension and hypertensive target-organ damage]. Kanno K; Hirata Y Nihon Rinsho; 2004 Mar; 62 Suppl 3():164-8. PubMed ID: 15171363 [No Abstract] [Full Text] [Related]
10. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Jeng AY Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451 [TBL] [Abstract][Full Text] [Related]
11. Is there a role for endothelin antagonists in diabetic renal disease? Jandeleit-Dahm K; Allen TJ; Youssef S; Gilbert RE; Cooper ME Diabetes Obes Metab; 2000 Jan; 2(1):15-24. PubMed ID: 11220349 [No Abstract] [Full Text] [Related]
12. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029 [TBL] [Abstract][Full Text] [Related]
14. Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme. Pollock DM; Shiosaki K; Sullivan GM; Opgenorth TJ Biochem Biophys Res Commun; 1992 Jul; 186(2):1146-50. PubMed ID: 1497648 [TBL] [Abstract][Full Text] [Related]
15. California dreamin' 'bout endothelin: emerging new therapeutics. Warner TD; Elliott JD; Ohlstein EH Trends Pharmacol Sci; 1996 May; 17(5):177-81. PubMed ID: 8669122 [TBL] [Abstract][Full Text] [Related]
16. [The role of endothelin in the realization of the length-strength ratio of vascular smooth muscles in rats]. Tkachenko MN; Sagach VF Fiziol Zh Im I M Sechenova; 1995 Sep; 81(9):60-4. PubMed ID: 8581054 [No Abstract] [Full Text] [Related]
17. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Doggrell SA Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501 [TBL] [Abstract][Full Text] [Related]